Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2023 | $4.00 → $2.00 | Neutral → Underperform | BofA Securities |
| 6/26/2023 | Buy → Hold | Stifel | |
| 6/26/2023 | Buy → Neutral | BofA Securities | |
| 6/26/2023 | Outperform → Mkt Perform | Raymond James | |
| 6/26/2023 | Outperform → Mkt Perform | William Blair | |
| 6/2/2023 | $23.00 → $32.00 | Hold → Buy | Stifel |
| 1/31/2023 | Mkt Perform → Outperform | William Blair | |
| 1/26/2023 | $35.00 | Mkt Perform → Outperform | Raymond James |
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
SC 13G/A - FIBROGEN INC (0000921299) (Subject)
SC 13G/A - FIBROGEN INC (0000921299) (Subject)
SC 13G/A - FIBROGEN INC (0000921299) (Subject)
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
10-Q - FIBROGEN INC (0000921299) (Filer)
8-K - FIBROGEN INC (0000921299) (Filer)
8-K - FIBROGEN INC (0000921299) (Filer)
Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) are expected in 1H 2025Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC anticipated in 1Q 2025Third quarter net revenue growth of 15% year over year, driven by strong performance of roxadustat in China, with year over year volume growth of 34% Reiterate full year net product revenue guidance of $135 million to $150 million, representing full year total roxadustat net sales in China1 between $330 million to $350 m
SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast Toll-free: 1-877-300-8521International investors: 1-412-317-6026Webcast: Click here To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. A replay of the webcast will also be available for a limited time on the "Events and Pres
SAN FRANCISCO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY. Thane Wettig, Chief Executive Officer of FibroGen, will deliver a company presentation on Tuesday, September 10 at 3:00 PM ET at the Lotte New York Palace Hotel. A live webcast of the presentation will be available here. FibroGen's management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright. A replay of the presentation will be posted,
Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) are expected in 1H 2025Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC anticipated in 1Q 2025Third quarter net revenue growth of 15% year over year, driven by strong performance of roxadustat in China, with year over year volume growth of 34% Reiterate full year net product revenue guidance of $135 million to $150 million, representing full year total roxadustat net sales in China1 between $330 million to $350 m
SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast Toll-free: 1-877-300-8521International investors: 1-412-317-6026Webcast: Click here To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. A replay of the webcast will also be available for a limited time on the "Events and Pres
Company implementing significant cost reduction plan in the U.S. due to results in late-stage pamrevlumab pancreatic cancer trials, including a reduction of U.S. workforce by approximately 75%Focus R&D investment on FG-3246 and PET46, a first-in-class anti-CD46 antibody-drug conjugate and companion PET imaging agent for metastatic castration-resistant prostate cancer (mCRPC) Presented compelling preliminary data from dose escalation portion of Phase 1b/2 investigator-sponsored study of FG-3246, in combination with enzalutamide, in patients with mCRPC at the 2024 American Society of Clinical Oncology Annual Meeting Topline results from Phase 2 portion of the study expected in 1H
Gainers Qualigen Therapeutics (NASDAQ:QLGN) shares moved upwards by 42.5% to $0.25 during Thursday's regular session. The company's market cap stands at $1.5 million. The company's, Q1 earnings came out 2 days ago. Sharps Technology (NASDAQ:STSS) stock rose 33.56% to $0.31. The market value of their outstanding shares is at $6.1 million. Autonomix Medical (NASDAQ:AMIX) shares increased by 21.43% to $0.78. The market value of their outstanding shares is at $14.6 million. Akso Health Group (NASDAQ:AHG) stock rose 11.68% to $1.29. The company's market cap stands at $189.2 million. Conduit Pharmaceuticals (NASDAQ:CDT) stock rose 10.74% to $0.71. The company's market cap stands at $52.3 mill
FibroGen Inc (NASDAQ:FGEN) shares initially traded higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical trial supply agreement with Regeneron. The Details: FibroGen announced that the FDA cleared its IND of FG-3165, allowing the company to initiate a Phase 1 clinical trial. FG-3165 is a galectin-9 targeted monoclonal antibody under development for treatment of solid tumors characterized by high Gal9 levels of expression. Phase 1 trials evaluating the safety and efficacy of FG-3165 in patients with select solid tumors are expected to begin enrollment in the second half of 2024. "To date, F
Shares of Healthequity Inc (NASDAQ:HQY) rose sharply in today's pre-market trading as the company reported better-than-expected first-quarter financial results. The company reported quarterly earnings of 80 cents per share which beat the analyst consensus estimate of 66 cents, according to data from Benzinga Pro. HealthEquity issued strong FY25 earnings guidance and also issued FY25 revenue guidance with its midpoint above expectations. Healthequity shares jumped 5.9% to $85.98 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers MicroAlgo Inc (NASDAQ:MLGO) rose 209.5% to $4.83 in today's pre-market trading. WiMi Hologram Cloud a
BofA Securities downgraded FibroGen from Neutral to Underperform and set a new price target of $2.00 from $4.00 previously
Stifel downgraded FibroGen from Buy to Hold
BofA Securities downgraded FibroGen from Buy to Neutral
SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities. The appointment is effective March 11, 2024. "Deyaa's leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need," said Thane Wettig, Chief Executive Officer of FibroGen. "We are excited to welcome him
Appoints Thane Wettig as Interim Chief Executive Officer Wettig succeeds Enrique Conterno and brings over 30 years of global pharmaceutical leadership SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced the appointment of Thane Wettig as the Company's interim Chief Executive Officer effective as of July 23, 2023. Mr. Wettig has served as FibroGen's Chief Commercial Officer and a key member of the senior leadership team since June 2020. Mr. Wettig succeeds Chief Executive Officer Enrique Conterno, who resigned due to personal reasons. To support Mr. Wettig, Mr. Conterno will serve as a Special Advisor to the CEO during a transition period. "Than
Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced the appointment of Bassem Elmankabadi, M.D., as senior vice president of clinical development. In this role, Dr. Elmankabadi will oversee strategy and execution of Blade's clinical development programs. "Dr. Elmankabadi has an extensive track record driving drug development from proof-of-concept through launch across multiple therapeutic areas," said Wendye Robbins, M.D., president and CEO of Blade. "I am thrilled to welcome Dr. Elmankabadi to the Blade team as we seek to advance our clinical-stage pipeline t